Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320162970> ?p ?o ?g. }
- W2320162970 endingPage "671" @default.
- W2320162970 startingPage "665" @default.
- W2320162970 abstract "This study evaluated the toxicity of high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF (G-CSF) given every 2 weeks and compared the dose-intensity achieved with this schedule with that obtained in a previous study we conducted in which the same regimen was given every 3 weeks without G-SCF (EC 21). The secondary objective was to explore the activity of this regimen.Between December 1991 and March 1994, 41 patients (pts), 19 with locally advanced breast cancer (LABC) and 22 with metastatic breast cancer (MBC), were given high-dose epirubicin (Hd-Epi) (120 mg/m2) and cyclophosphamide (CTX) (600 mg/m2) on day 1 every 14 days (EC 14) plus granulocyte colony-stimulating factor (G-CSF) (5 mcg/kg/d s.c. on days 2-12). A total of 8 cycles in LABC pts (4 pre- and post-surgery), and 6-8 cycles in MCB pts were administered. The results were compared with those obtained in the previous study.The incidence of WHO grade 3-4 neutropenia was significantly reduced in the EC 14 + G-CSF regimen (25.2% vs. 46.8% in 214 and 250 evaluable cycles, respectively, p<0.0001), as well as the incidence of neutropenic fever (7% vs. 3%, p=0.05). Grade 3-4 anemia (36.6% vs. 8% pts, p=0.001) and grade 3-4 thrombocytopenia (17.1% vs. 0 pts, p=0.002), were significantly more frequent in EC 14 + G-CSF. No significant differences in the other side effects were found. A total of 17 of 207 of the cycles (8.2%) were delayed in the EC 14 + G-CSF vs. 58/271 (21.4%) in the EC 21 (p<0.0001). The main reasons for these treatment delays were neutropenia (1% vs. 15%), anemia (3% vs. 0) and thrombocytopenia (1% vs. 0). As a result of treatment acceleration and differences in dose delays, the patients on EC 14 + G-CSF received a higher dose-intensity (Epi 58.51 mg/m2/wk vs. 36.8 mg/m2/wk; CTX 292.52 mg/m2/wk vs. 182.9 mg/m2/wk). A complete response at surgery was obtained in 9/19 (47.4%) LABC pts. An objective CR was obtained in 11/22 MBC pts (50%) and a partial response in 8/22 (36.4%), yielding an overall response rate of 86.4%.Hd-Epi + CTX is very active against both LABC and MBC. The administration of G-CSF allows dose intensification of both drugs (a 59.5% increase of the actual dose intensity) with acceptable clinical tolerance (a lower incidence of neutropenia but a higher incidence of anemia and thrombocytopenia). Only a specifically designed phase III trial will lead to definitive conclusions regarding the greater antitumor activity of accelerated CSF-including regimens as compared to standard chemotherapy for advanced breast cancer." @default.
- W2320162970 created "2016-06-24" @default.
- W2320162970 creator A5011707388 @default.
- W2320162970 creator A5023511506 @default.
- W2320162970 creator A5033258883 @default.
- W2320162970 creator A5043610927 @default.
- W2320162970 creator A5054940269 @default.
- W2320162970 creator A5056071190 @default.
- W2320162970 creator A5080823945 @default.
- W2320162970 creator A5086743021 @default.
- W2320162970 date "1995-09-01" @default.
- W2320162970 modified "2023-09-27" @default.
- W2320162970 title "Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer" @default.
- W2320162970 cites W1490707610 @default.
- W2320162970 cites W1785581158 @default.
- W2320162970 cites W1836115940 @default.
- W2320162970 cites W1900639705 @default.
- W2320162970 cites W1976476604 @default.
- W2320162970 cites W1987951694 @default.
- W2320162970 cites W2017921725 @default.
- W2320162970 cites W2036338253 @default.
- W2320162970 cites W2058681718 @default.
- W2320162970 cites W2065910438 @default.
- W2320162970 cites W2074454485 @default.
- W2320162970 cites W2079088649 @default.
- W2320162970 cites W2108899863 @default.
- W2320162970 cites W2253920138 @default.
- W2320162970 cites W2265230738 @default.
- W2320162970 cites W2308168543 @default.
- W2320162970 cites W2338649218 @default.
- W2320162970 cites W2341557816 @default.
- W2320162970 cites W2466305728 @default.
- W2320162970 cites W4236767488 @default.
- W2320162970 doi "https://doi.org/10.1093/oxfordjournals.annonc.a059282" @default.
- W2320162970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8664187" @default.
- W2320162970 hasPublicationYear "1995" @default.
- W2320162970 type Work @default.
- W2320162970 sameAs 2320162970 @default.
- W2320162970 citedByCount "26" @default.
- W2320162970 countsByYear W23201629702016 @default.
- W2320162970 countsByYear W23201629702019 @default.
- W2320162970 countsByYear W23201629702021 @default.
- W2320162970 crossrefType "journal-article" @default.
- W2320162970 hasAuthorship W2320162970A5011707388 @default.
- W2320162970 hasAuthorship W2320162970A5023511506 @default.
- W2320162970 hasAuthorship W2320162970A5033258883 @default.
- W2320162970 hasAuthorship W2320162970A5043610927 @default.
- W2320162970 hasAuthorship W2320162970A5054940269 @default.
- W2320162970 hasAuthorship W2320162970A5056071190 @default.
- W2320162970 hasAuthorship W2320162970A5080823945 @default.
- W2320162970 hasAuthorship W2320162970A5086743021 @default.
- W2320162970 hasBestOaLocation W23201629701 @default.
- W2320162970 hasConcept C121608353 @default.
- W2320162970 hasConcept C126322002 @default.
- W2320162970 hasConcept C126894567 @default.
- W2320162970 hasConcept C141071460 @default.
- W2320162970 hasConcept C2775930923 @default.
- W2320162970 hasConcept C2776694085 @default.
- W2320162970 hasConcept C2776755627 @default.
- W2320162970 hasConcept C2777063308 @default.
- W2320162970 hasConcept C2777767877 @default.
- W2320162970 hasConcept C2780835546 @default.
- W2320162970 hasConcept C2781413609 @default.
- W2320162970 hasConcept C530470458 @default.
- W2320162970 hasConcept C71924100 @default.
- W2320162970 hasConcept C90924648 @default.
- W2320162970 hasConceptScore W2320162970C121608353 @default.
- W2320162970 hasConceptScore W2320162970C126322002 @default.
- W2320162970 hasConceptScore W2320162970C126894567 @default.
- W2320162970 hasConceptScore W2320162970C141071460 @default.
- W2320162970 hasConceptScore W2320162970C2775930923 @default.
- W2320162970 hasConceptScore W2320162970C2776694085 @default.
- W2320162970 hasConceptScore W2320162970C2776755627 @default.
- W2320162970 hasConceptScore W2320162970C2777063308 @default.
- W2320162970 hasConceptScore W2320162970C2777767877 @default.
- W2320162970 hasConceptScore W2320162970C2780835546 @default.
- W2320162970 hasConceptScore W2320162970C2781413609 @default.
- W2320162970 hasConceptScore W2320162970C530470458 @default.
- W2320162970 hasConceptScore W2320162970C71924100 @default.
- W2320162970 hasConceptScore W2320162970C90924648 @default.
- W2320162970 hasIssue "7" @default.
- W2320162970 hasLocation W23201629701 @default.
- W2320162970 hasLocation W23201629702 @default.
- W2320162970 hasOpenAccess W2320162970 @default.
- W2320162970 hasPrimaryLocation W23201629701 @default.
- W2320162970 hasRelatedWork W1969729309 @default.
- W2320162970 hasRelatedWork W1999426713 @default.
- W2320162970 hasRelatedWork W2102434336 @default.
- W2320162970 hasRelatedWork W2114989931 @default.
- W2320162970 hasRelatedWork W2320162970 @default.
- W2320162970 hasRelatedWork W2332362313 @default.
- W2320162970 hasRelatedWork W2358269044 @default.
- W2320162970 hasRelatedWork W2398175517 @default.
- W2320162970 hasRelatedWork W2418276413 @default.
- W2320162970 hasRelatedWork W3143857483 @default.
- W2320162970 hasVolume "6" @default.
- W2320162970 isParatext "false" @default.
- W2320162970 isRetracted "false" @default.